How these super enzymes could revolutionise what we think about plastic

What if you could add enzymes to plastic, which would decompose the plastic into safe and biodegradable parts after use?

Is carob the new cocoa? NUS researchers fine-tune carob as chocolate alternative

They came up with two techniques to better mimic the taste of cocoa – bitter and sweet. Read more at straitstimes.com. Read ...

Cosmetic fillers can cause deadly complication, experts warn — but new tech exposes it

Breakthrough research shows ultrasound can spot filler-related vascular complications early, enabling precise treatment and ...

What happens to your stomach when you chew cardamom or elaichi after every meal? Doctor explains benefits for digestion

From reducing bloating and acidity to refreshing your breath, chewing cardamom after meals is a simple habit that supports ...
Indian Defence Review on MSN

Scientists develop DNA-based cassette tape capable of storing 36 petabytes of data

Scientists in China have created a cassette tape that stores data using DNA strands.
India Water Portal

FAQ: Everything you need to know about the blue economy

Deep dive into the challenges and opportunities of India's Blue Economy. Learn about the Deep Ocean Mission, the risks of ...
Le Lézard

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Global biopharma leader CSL today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® ...

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline ...

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...
Le Lézard

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...